These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10188788)

  • 1. Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease.
    Sedman AJ; Bockbrader H; Schwarz RD
    Life Sci; 1995; 56(11-12):877-82. PubMed ID: 10188788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization.
    Schwarz RD; Callahan MJ; Coughenour LL; Dickerson MR; Kinsora JJ; Lipinski WJ; Raby CA; Spencer CJ; Tecle H
    J Pharmacol Exp Ther; 1999 Nov; 291(2):812-22. PubMed ID: 10525104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional brain distribution and binding of the muscarinic receptor agonist CI-979 studied by positron emission tomography in the monkey.
    Hartvig P; Torstenson R; Bjurling P; Fasth KJ; Längström B; Nordberg A
    Dement Geriatr Cogn Disord; 1997; 8(5):259-66. PubMed ID: 9298626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease.
    Adamus WS; Leonard JP; Tröger W
    Life Sci; 1995; 56(11-12):883-90. PubMed ID: 10188789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832.
    Jaen J; Barrett S; Brann M; Callahan M; Davis R; Doyle P; Eubanks D; Lauffer D; Lauffer L; Lipinski W
    Life Sci; 1995; 56(11-12):845-52. PubMed ID: 10188784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
    Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
    Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
    Messer WS
    J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of a muscarinic cholinergic agonist on acetylcholine and dopamine receptors in the monkey brain studied with positron emission tomography.
    Hartvig P; Nordberg A; Torstenson R; Sjöberg P; Fasth KJ; Långström B
    Dement Geriatr Cogn Disord; 2002; 13(4):199-204. PubMed ID: 12006729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonism of scopolamine-induced memory impairments in rats by the muscarinic agonist RU 35,926 (CI-979).
    M'Harzi M; Palou AM; Oberlander C; Barzaghi F
    Pharmacol Biochem Behav; 1995 May; 51(1):119-24. PubMed ID: 7617721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology.
    Tecle H; Schwarz RD; Barrett SD; Callahan MJ; Caprathe BW; Davis RE; Doyle P; Emmerling M; Lauffer DJ; Mirzadegan T; Moreland DW; Lipiniski W; Nelson C; Raby C; Spencer C; Spiegel K; Thomas AJ; Jaen JC
    Pharm Acta Helv; 2000 Mar; 74(2-3):141-8. PubMed ID: 10812951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication.
    Chambon C; Jatzke C; Wegener N; Gravius A; Danysz W
    Eur J Pharmacol; 2012 Dec; 697(1-3):73-80. PubMed ID: 23085025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
    Bromidge SM; Brown F; Cassidy F; Clark MS; Dabbs S; Hadley MS; Hawkins J; Loudon JM; Naylor CB; Orlek BS; Riley GJ
    J Med Chem; 1997 Dec; 40(26):4265-80. PubMed ID: 9435896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
    Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
    J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling.
    Sabb AL; Husbands GM; Tokolics J; Stein RP; Tasse RP; Boast CA; Moyer JA; Abou-Gharbia M
    Bioorg Med Chem Lett; 1999 Jul; 9(14):1895-900. PubMed ID: 10450949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man.
    Wienrich M; Meier D; Ensinger HA; Gaida W; Raschig A; Walland A; Hammer R
    Life Sci; 2001 Apr; 68(22-23):2593-600. PubMed ID: 11392631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders.
    Cereda E; Brambilla A; Ezhaya A; Gaida W; Mendla K; Monferini E; Pitsikas N; Schiavi GB; Sagrada A
    Eur J Drug Metab Pharmacokinet; 1994; 19(3):179-83. PubMed ID: 7867659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
    Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist.
    Emmerling MR; Gregor VE; Schwarz RD; Scholten JD; Callahan MJ; Lee C; Moore CJ; Raby C; Lipinski WJ; Davis RE
    Mol Neurobiol; 1994; 9(1-3):93-106. PubMed ID: 7888109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined cerebral blood flow effects of a cholinergic agonist (milameline) and a verbal recognition task in early Alzheimer's disease.
    Trollor JN; Sachdev PS; Haindl W; Brodaty H; Wen W; Walker BM
    Psychiatry Clin Neurosci; 2006 Oct; 60(5):616-25. PubMed ID: 16958947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
    Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
    J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.